Gotowe bibliografie tematyczne / Acute Leukaemia - Treatment

Spis treści

  1. Artykuły w czasopismach
  2. Rozprawy doktorskie
  3. Książki
  4. Części książek
  5. Streszczenia konferencji

Gotowa bibliografia na temat „Acute Leukaemia - Treatment”

Autor: Grafiati
Data publikacji: 4 czerwca 2021
Data aktualizacji: 25 stycznia 2023

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Acute Leukaemia - Treatment”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "Acute Leukaemia - Treatment"

1

Kuzmits, Rudolf, Paul Aiginger, Matthias M. Müller, Günter Steurer, and Werner Linkesch. "Assessment of the sensitivity of leukaemic cells to cytotoxic drugs by bioluminescence measurement of ATP in cultured cells." Clinical Science 71, no. 1 (July 1, 1986): 81–88. http://dx.doi.org/10.1042/cs0710081.

Pełny tekst źródła
Streszczenie:
1. A short-term test in vitro is described, which can be used to detect resistance to cytostatic agents in leukaemic cells. Leukaemic cell suspensions were incubated with cytostatic agents and the resulting intracellular ATP concentrations were measured by a bioluminescence ATP assay. 2. There was a clear dose-effect relationship in acute leukaemia and chronic lymphocytic leukaemia cells for drugs used in the treatment of leukaemias. A good correlation was found between the ATP content of leukaemic cells and cell viability as determined by the trypan blue dye exclusion test. 3. Preliminary ind
Style APA, Harvard, Vancouver, ISO itp.
2

Ivanovic, Mirjana, Olivera Jovicic, Jelena Mandic, Dusko Bogetic, and Marcello Maddalone. "Oral manifestations of acute leukaemia." Srpski arhiv za celokupno lekarstvo 139, no. 1-2 (2011): 103–6. http://dx.doi.org/10.2298/sarh1102103i.

Pełny tekst źródła
Streszczenie:
Acute leukaemia is the most common form of chilhood cancer. The aim of this paper was to underline the importance of oral manifestations in children with acute leukaemia. The disease and its treatment can directly or indirectly affect oral health. Oral manifestations are gingival inflammation and enlargement. Leukaemic cells are capable of infiltrating the gingiva and the deeper periodontal tissues which leads to ulceration and infection of oral tissues. Gingival bleeding is a common sign in patients with leukaemia. Symptoms include local lymphadenopathy, mucous membrane Petechiae and ecchymos
Style APA, Harvard, Vancouver, ISO itp.
3

Skarsgård, Lisa Stenman, Mattias K. Andersson, Marta Persson, Ann-Cathrine Larsen, Sarah E. Coupland, Göran Stenman, and Steffen Heegaard. "Clinical and genomic features of adult and paediatric acute leukaemias with ophthalmic manifestations." BMJ Open Ophthalmology 4, no. 1 (October 2019): e000362. http://dx.doi.org/10.1136/bmjophth-2019-000362.

Pełny tekst źródła
Streszczenie:
ObjectiveTo describe the clinicopathological and genomic features of nine patients with primary and secondary orbital/ocular manifestations of leukaemia.MethodsAll orbital/ocular leukaemic specimens from 1980 to 2009 were collected from the Danish Register of Pathology. In six cases, medical records and formalin-fixed, paraffin-embedded blocks were available. Three cases from the Department of Pathology, Royal Liverpool University Hospital, were also included. Immunophenotypes and MYB oncoprotein expression were ascertained by immunohistochemistry. Genomic imbalances were analysed with compara
Style APA, Harvard, Vancouver, ISO itp.
4

Arruda, Walter Oleschko, María Belén Montú, Marcelo de Souza R. de Oliveira, and Ricardo Ramina. "Acute myeloid leukaemia induced by mitoxantrone: case report." Arquivos de Neuro-Psiquiatria 63, no. 2a (June 2005): 327–29. http://dx.doi.org/10.1590/s0004-282x2005000200024.

Pełny tekst źródła
Streszczenie:
Mitoxantrone (MX) is an immunosupressant drug used in secondarily progressive multiple sclerosis (SPMS) and in relapsing-remitting multiple sclerosis (RRMS). It has a leukemogenesis potential induced by cytogenetic abnormalities, though with a low incidence. Promyelocitic leukaemia (type M3) and other forms of acute myeloblastic leukaemias (M4 and M5) have been described in a few MS patients who received MX during their treatment. We describe a white female patient, 47 year-old, with SPMS (EDSS = 4) with 14 years of disease. She received MX during her disease and developed acute promyelocytic
Style APA, Harvard, Vancouver, ISO itp.
5

Bhalla, Amit. "Clofarabine: a next-generation deoxyadenosine analogue." International Journal of Basic & Clinical Pharmacology 7, no. 5 (April 23, 2018): 1048. http://dx.doi.org/10.18203/2319-2003.ijbcp20181660.

Pełny tekst źródła
Streszczenie:
Acute lymphoblastic leukaemia (ALL) is the most common of the paediatric leukaemias. It is estimated that the use of modern combination chemotherapy results in long-term remission in nearly 80% of children diagnosed with ALL. Despite therapy advances, approximately 20% of children with ALL, experience leukaemia relapse. Clofarabine (2-chloro-2’-fluoro-2’-deoxy-9-β-D-arabinofuranosyladenine) is a second-generation nucleoside analogue and is structurally related to fludarabine and cladribine which are widely used in the treatment of lymphoproliferative disorders. Clofarabine exhibits greater aff
Style APA, Harvard, Vancouver, ISO itp.
6

Burnett, Alan K. "Treatment of acute myeloid leukaemia." Clinical Medicine 13, Suppl 6 (December 2013): s58—s61. http://dx.doi.org/10.7861/clinmedicine.13-6-s58.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Apostolidou, Effrosyni, Ronan Swords, Yesid Alvarado, and Francis J. Giles. "Treatment of Acute Lymphoblastic Leukaemia." Drugs 67, no. 15 (2007): 2153–71. http://dx.doi.org/10.2165/00003495-200767150-00004.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

LÖWENBERG, B. "Treatment of acute myelogenous leukaemia." Journal of Internal Medicine 242 (July 1997): 17–22. http://dx.doi.org/10.1111/joim.1997.242.s740.17.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Omura, GeorgeA. ""MAINTENANCE TREATMENT" FOR ACUTE LEUKAEMIA." Lancet 328, no. 8516 (November 1986): 1154. http://dx.doi.org/10.1016/s0140-6736(86)90553-2.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Burnett, AK, and OB Eden. "The treatment of acute leukaemia." Lancet 349, no. 9047 (January 1997): 270–75. http://dx.doi.org/10.1016/s0140-6736(96)08086-5.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Rozprawy doktorskie na temat "Acute Leukaemia - Treatment"

1

Thornton, Nadia. "L-alanosine : selective treatment in relapsed childhood acute lymphoblastic leukaemia." Thesis, University of Newcastle Upon Tyne, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.440588.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Johnson, Peter R. E. "The biology and treatment of acute myeloid leukaemia in elderly patients." Thesis, University of Aberdeen, 1992. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.306856.

Pełny tekst źródła
Streszczenie:
Acute myeloid leukaemia (AML) is predominantly a disease of the elderly; the median age is 64 years and almost 60% of cases are over 60 years old. Unfortunately however, the treatment of AML in elderly patients is generally unsatisfactory with significantly poorer remission rates and overall survival than in younger patients. We have designed a novel treatment regimen consisting of Mitozantrone and Cytosine Arabinoside specifically for elderly patients and have evaluated the regimen in 104 patients over 60 years old in the North West region. The complete remission rate was 58%, the median dura
Style APA, Harvard, Vancouver, ISO itp.
3

Lehtinen, S. (Satu). "Neurotoxicity in children after treatment for acute lymphoblastic leukaemia and methotrexate neurotoxicity in a controlled animal model." Doctoral thesis, University of Oulu, 2003. http://urn.fi/urn:isbn:9514270339.

Pełny tekst źródła
Streszczenie:
Abstract In the Nordic countries, event-free survival (EFS) exceeds 80% in certain groups of children treated for acute lymphoblastic leukaemia (ALL). With the improved cure rates, however, there are more children suffering from neurological late effects, especially due to therapy directed at the central nervous system (CNS). The aim of this study is to examine the changes taking place in the nervous system after leukemia treatment and to evaluate the role of treatment in these changes in patients and in an animal model. Twenty-seven ALL survivors and healthy controls were examined by means o
Style APA, Harvard, Vancouver, ISO itp.
4

Hallböök, Helene. "Acute lymphoblastic leukaemia in adult patients : studies of prognostic factors, treatment results and in vitro cellular drug resistance /." Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5768.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Hallböök, Helene. "Acute Lymphoblastic Leukaemia in Adult Patients : Studies of Prognostic Factors, Treatment Results and in vitro Cellular Drug Resistance." Doctoral thesis, Uppsala University, Department of Medical Sciences, 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5768.

Pełny tekst źródła
Streszczenie:
<p>Treatment results and clinical characteristics in adult acute lymphoblastic leukaemia (ALL) were evaluated regarding three issues: a new treatment with cytarabine up-front, stem cell transplantation and a comparison between adult and paediatric treatment protocols. All studies were conducted on a national basis. Furthermore, activity of imatinib was investigated by in vitro cytotoxicity assay. </p><p>The national protocol was evaluated in 153 adult ALL patients. A high complete remission rate, 86%, was achieved with 29% overall survival at 3-years. Favourable outcome was identified in patie
Style APA, Harvard, Vancouver, ISO itp.
6

Krishnan, Shekhar. "In vitro evaluation of asparagine endopeptidase as a candidate biomarker of treatment failure in childhood acute lymphoblastic leukaemia." Thesis, Queen Mary, University of London, 2011. http://qmro.qmul.ac.uk/xmlui/handle/123456789/1294.

Pełny tekst źródła
Streszczenie:
Background Although cure rates in childhood acute lymphoblastic leukaemia (ALL) approach 90%, relapses, particularly central nervous system (CNS) relapses, pose a significant therapeutic challenge. Prevention of relapses requires better predictive biomarkers. Towards this end, global gene-expression microarray screens of primary ALL samples were performed. Overexpression of the lysosomal cysteine protease, asparagine endopeptidase (AEP) was identified in adverse-risk progenitor-B ALL genotypes. AEP overexpression in adult human epithelial cancers has been linked to metastasis and adverse progn
Style APA, Harvard, Vancouver, ISO itp.
7

Liem, Natalia Women's &amp Children's Health Faculty of Medicine UNSW. "The development of an in vivo model to study the biology and treatment of childhood acute lymphoblastic leukaemia (ALL)." Awarded by:University of New South Wales. Women's & Children's Health, 2007. http://handle.unsw.edu.au/1959.4/40537.

Pełny tekst źródła
Streszczenie:
Relapsed ALL remams one of the most common causes of death from disease in children. Broad-range drug resistance is often associated with relapse, although its underlying molecular mechanisms remained poorly understood. The aim of this thesis was to establish an in vivo model using the non-obese diabetic/severe combined immunodeficient (NOD/SCID) mouse strain, to facilitate the engraftment, expansion and characterisation of childhood ALL cells, obtained from patients at diagnosis or relapse. Mice were inoculated with leukaemia cells from patients' biopsies and engraftment was monitored by the
Style APA, Harvard, Vancouver, ISO itp.
8

Fordham, Sarah Elizabeth. "DNA mismatch repair and cellular response to cytarabine : implications for the pathogenesis and treatment of therapy-related acute myeloid leukaemia." Thesis, University of Newcastle Upon Tyne, 2011. http://hdl.handle.net/10443/1366.

Pełny tekst źródła
Streszczenie:
The DNA mismatch repair (MMR) pathway is responsible for correction of replicative errors, hence is a key factor in maintenance of genomic stability. Paradoxically, functional DNA MMR also mediates the cytotoxicity of certain chemotherapeutic DNA damaging agents. Poor treatment response in therapy-related acute myeloid leukaemia (t-AML) is influenced by a number of factors, one of which might be chemoresistance due to acquired defects in DNA MMR. Using a range of paired MMR proficient and deficient cell lines, investigations herein demonstrate that DNA MMR status mediates response to nucleosid
Style APA, Harvard, Vancouver, ISO itp.
9

Burrett, Julie Ann. "Identification of randomized trials for inclusion in meta-analyses of treatments for childhood acute lymphoblastic leukaemia, and investigation of factors leading to publication bias." Thesis, Open University, 2003. http://oro.open.ac.uk/22376/.

Pełny tekst źródła
Streszczenie:
<b><u>Purpose</u></b>: Some randomized trials are reported widely, while others remain unpublished. It is essential to systematic reviewers and meta-analysts that factors leading to publication bias in the form of delayed or non-publication of an eligible study are identified. This thesis is an attempt to do this. <br></br><br></br> <b><u>Data</u></b>: The set of randomized trials identified by the Childhood Acute Lymphoblastic Leukaemia (ALL) Collaborative Group was used. This consists of 149 trials comprising 243 randomized comparisons (randomizations), starting prior to 1 January 1988, repo
Style APA, Harvard, Vancouver, ISO itp.
10

"Daunorubicin kinetics and drug resistance in leukaemia." Thesis, University of Technology, Sydney. Faculty of Science, 1996. http://hdl.handle.net/10453/20146.

Pełny tekst źródła
Streszczenie:
University of Technology, Sydney. Faculty of Science.<br>The aims of this thesis were to examine: (1) plasma and cellular pharmacokinetics of daunorubicin and its major metabolite daunorubicinol in patients with acute leukaemia, and the relationships between pharmacokinetics, patient response and the presence of P glycoprotein; (2) actions of the multidrug resistance reversing agents cyclosporin A and trifluoperazine, at clinically achievable concentrations, on daunorubicin accumulation and retention in human leukaemia cell lines and patients with acute leukaemia; and (3) effect of daunorubici
Style APA, Harvard, Vancouver, ISO itp.

Książki na temat "Acute Leukaemia - Treatment"

1

National Institute for Clinical Excellence. Guidance on the use of imatinib for chronic myeloid leukaemia. London: National Institute for Clinical Excellence, 2003.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

National Institute for Clinical Excellence. Guidance on the use of imatinib for chronic myeloid leukaemia. London: National Institute for Clinical Excellence, 2002.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Rooney, Maria Anne. An evaluation of the immune competence of children with common Acute Lymphoblastic Leukaemia, both during and post-treatment, by an investigation of the Lymphocyte sub-populations using monoclonal antibodies and the Alkaline Phosphatase Anti-Alkaline Phosphatase technique. [s.1: The Author], 1989.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Mendez, Irvin. Acute Myeloid Leukaemia: Symptoms, Diagnosis and Treatment. Nova Science Publishers, Incorporated, 2018.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

M, Carella Angelo, ed. Chronic myeloid leukaemia: Biology and treatment. London: Martin Dunitz, 2001.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Goldman, John M., Angelo M. Carella, George Q. Daley, Connie J. Eaves, and Hehlmann Rudiger. Chronic Myeloid Leukaemia: Biology and Treatment. Taylor & Francis Group, 2003.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

McCann, Shaun R. Leukaemia. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198717607.003.0007.

Pełny tekst źródła
Streszczenie:
The word leukaemia still is associated with foreboding and a fear of premature death. Steady advances have been made in the treatment of childhood leukaemia but, with notable exceptions, the same is not true in adults. The so-called genetic/molecular revolution has extended the understanding of the pathogenesis of many forms of leukaemia but, as yet, has rarely facilitated cure. With the introduction of tyrosine kinase inhibitor therapy, chronic myeloid leukaemia is the obvious exception but it still needs to be seen as to whether the cytogenetic/molecular revolution can provide cures for many
Style APA, Harvard, Vancouver, ISO itp.
8

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, and Gareth Morris-Stiff. Bone and soft tissue malignancies. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199689842.003.0025.

Pełny tekst źródła
Streszczenie:
Haematological malignancies examines the epidemiology, genetics, clinical presentation and classification of these diseases, and presents current treatment approaches for each. First are the acute leukaemias, and the management of acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). Chronic myeloid leukaemia, its genetics and sensitivity to tyrosine kinase inhibitors, is described. Myelodysplastic syndromes and their management, are followed by chronic lymphoid leukaemias, a large heterogeneous group of diseases, and their treatment. Hodgkin lymphoma, its pathology and presen
Style APA, Harvard, Vancouver, ISO itp.
9

Cutter, David, and Martin Scott-Brown. Treatment of cancer. Edited by Patrick Davey and David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0325.

Pełny tekst źródła
Streszczenie:
The variety of conditions that are considered to be ‘cancer’ is extremely wide, with marked variation in the management approach from disease to disease. A common feature in the management of malignant conditions, however, is the involvement of a wide range of medical professionals at different stages of the patient pathway. This commonly includes physicians, surgeons, radiologists, pathologists, medical oncologists, radiation oncologists, and specialist nurses, as well as a plethora of other allied disciplines. As such, a practice that has been widely adopted is to work as a multidisciplinary
Style APA, Harvard, Vancouver, ISO itp.
10

McCann, Shaun R. Molecules, genes, and gene therapy. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198717607.003.0009.

Pełny tekst źródła
Streszczenie:
The twenty-first century has brought many innovations in haematology, with improved diagnostic technology, which may inform treatment choices for malignant diseases, and a better understanding of the genetics and/or epigenetics underlying many diseases. Unfortunately, the aetiology of most of these diseases still eludes us, and some common diseases such as sickle cell disease await simple, inexpensive, and widely available curative treatment. For reasons that are often obscure, some diseases have become fashionable and attract large research financial backing, whereas some do not. With the adv
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Części książek na temat "Acute Leukaemia - Treatment"

1

Jacobs, P., L. Wood, and N. Novitzky. "Treatment of Adult Acute Lymphoblastic Leukaemia." In Acute Leukemias II, 428–31. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74643-7_79.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Bader, Peter, Franco Locatelli, and Christina Peters. "Paediatric Acute Lymphoblastic Leukaemia (ALL)." In The EBMT/EHA CAR-T Cell Handbook, 57–59. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-94353-0_10.

Pełny tekst źródła
Streszczenie:
AbstractAcute lymphoblastic leukaemia (ALL) is the most frequent malignant disease in childhood and adolescence, with an annual incidence of approximately 3–4 cases per 100,000 children under 15 years of age. Multimodal chemotherapy forms the base of current ALL treatment. Based on excellent national and international collaboration in consecutive prospective, randomized clinical trials, the prognosis of childhood ALL has significantly improved over time. Currently, up to 90% of all paediatric patients with ALL will survive.
Style APA, Harvard, Vancouver, ISO itp.
3

Rees, J. K. H., R. Gray, and F. G. J. Hayhoe. "The Ninth British Medical Research Council Trial for the Treatment of Acute Myeloid Leukaemia." In Acute Leukemias, 35–37. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-71213-5_6.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Ortega, J. J., G. Javier, and T. Olive. "Treatment of Standard- and High-Risk Childhood Acute Lymphoblastic Leukaemia with Two CNS Prophylaxis Regimens." In Acute Leukemias, 483–92. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-71213-5_85.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Reizenstein, Peter. "The Use of Biological Response Modifiers in Acute Myeloid Leukaemia." In New Approaches to the Treatment of Leukemia, 79–86. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-75484-5_3.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

McCulloch, E. A. "Biological Characteristics of Acute Myeloblastic Leukaemia Contributing to Management Strategy." In New Approaches to the Treatment of Leukemia, 87–116. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-75484-5_4.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Davis, C. L., A. Z. S. Rohatiner, J. Amess, J. Lim, and T. A. Lister. "Treatment of Recurrent Acute Myelogenous Leukaemia at a Single Centre Over a 10-Year Period." In Acute Leukemias II, 339–41. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74643-7_64.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Rohatiner, A. Z. S., R. Bassan, R. Battista, J. E. Kingston, J. Amess, M. Carter, A. M. Oza, et al. "High-Dose Cytosine Arabinoside in the Treatment of Acute Lymphoblastic Leukaemia." In Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, 437–41. Berlin, Heidelberg: Springer Berlin Heidelberg, 1994. http://dx.doi.org/10.1007/978-3-642-78350-0_78.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Barnett, M. J., J. E. Kingston, A. Miller, A. Z. S. Rohatiner, M. A. Horton, M. F. Greaves, J. S. Malpas, and T. A. Lister. "Treatment of Minimal Residual Disease in “Poor Risk” Acute Lymphoblastic Leukaemia with High-Dose Cytosine Arabinoside." In Minimal Residual Disease in Acute Leukemia 1986, 205–10. Dordrecht: Springer Netherlands, 1986. http://dx.doi.org/10.1007/978-94-009-4273-8_19.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Tobler, A., and H. P. Koeffler. "Differentiation inducers and their potential use in the treatment of acute myelogenous leukaemia." In Cancer Biology and Medicine, 163–81. Dordrecht: Springer Netherlands, 1992. http://dx.doi.org/10.1007/978-94-009-0385-2_6.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Streszczenia konferencji na temat "Acute Leukaemia - Treatment"

1

Guindo, P. Nieto, H. Mateo Carrasco, FD Fernandez Gines, and E. Molina Cuadrado. "CP-137 Economic analysis of azacitidine versus decitabine for the treatment of acute myeloid leukaemia." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.136.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Megías-Vericat, JE, P. Montesinos, MJ Herrero, V. Bosó, F. Moscardó, L. Rojas, D. Martínez-Cuadrón, SF Aliño, MA Sanz, and JL Poveda. "PKP-003 Influence of cytarabine metabolic pathway polymorphisms in effectiveness of acute myeloid leukaemia induction treatment." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.431.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Soliman, Ranin, Carl Heneghan, Nancy Bolous, Iman Sidhom, Sonia Ahmed, Nia Roberts, Jason Oke, and Alaa Elhaddad. "122 Systematic review of costs and cost-effectiveness of treatment for relapsed/refractory acute leukaemia in children." In EBM Live. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/ebm-2022-ebmlive.37.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Soliman, Ranin, Carl Heneghan, Nancy Bolous, Iman Sidhom, Sonia Ahmed, Nia Roberts, Jason Oke, and Alaa Elhaddad. "173 Systematic review of costs and cost-effectiveness of treatment for relapsed/refractory acute leukaemia in children." In Preventing Overdiagnosis Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/bmjebm-2022-podabstracts.94.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Agraz-Doblas, A., C. Bueno, P. Schneider, C. Revilla, T. Moreno, P. Ballerini, M. Bardini, RW Stam, P. Menéndez, and I. Varela. "PO-315 The mutational and transcriptome landscape of infant B-cell acute lymphoblastic leukaemia: the INTERFANT treatment protocol experience." In Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.345.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Lopez-Montero, E., A. Mosquera-Torre, M. Touris-Lores, B. Sanchez-Iglesias, B. Bernardez-Ferran, and MJ Lamas-Diaz. "PS-086 Adding low dose allopurinol as hepatoprotector to the maintenance treatment with mercaptopurine in children with acute lymphoblastic leukaemia." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.592.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Grey, HET, and A. Davidson. "G555(P) Does the type of steroid used in the treatment of acute lymphoblastic leukaemia in childhood influence adult weight?" In Royal College of Paediatrics and Child Health, Abstracts of the RCPCH Conference and exhibition, 13–15 May 2019, ICC, Birmingham, Paediatrics: pathways to a brighter future. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2019. http://dx.doi.org/10.1136/archdischild-2019-rcpch.538.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Valencia, JC del Río, MRuiz de Villegas Garcia Pelayo, RTamayo Bermejo, and I. Muñoz Castillo. "4CPS-105 Blinatumomab for the treatment of the relapse b-precursor acute lymphoblastic leukaemia in a paediatric patient: a case report." In Abstract Book, 23rd EAHP Congress, 21st–23rd March 2018, Gothenburg, Sweden. British Medical Journal Publishing Group, 2018. http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.196.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Huynh, T., D. Vidovic, C. Dean, K. Lee, I. Weaver, and P. Marcato. "PO-372 Investigating the epigenetic changes underlying combination treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide." In Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.400.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Del Río Valencia, JC, C. Ortega De La Cruz, T. Chinchilla Alarcón, and I. Muñoz Castillo. "4CPS-113 Inotuzumab–ozogamizin for the treatment of relapse B precursor acute lymphoblastic leukaemia in an adult patient: a case report." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.214.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany rozszerzonymi bibliografiami na temat „Acute Leukaemia - Treatment” dla poszczególnych typów źródeł:
Artykuły w czasopismach Książki
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii